Latanoprost/Timolol

Timolol maleate and latanoprost, the active ingredients in Latanoprost/Timolol, are a beta‑blocker and a prostaglandin analog presented as eye drops for ocular use. They lower intraocular pressure in patients with open‑angle glaucoma or ocular hypertension.

GNH USA supplies Latanoprost/Timolol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost/Timolol is indicated for conditions affecting intraocular pressure within the glaucoma disease family.

Primary open‑angle glaucoma: reduces intraocular pressure to help prevent optic nerve damage. Ocular hypertension: lowers eye pressure to reduce the risk of progression to glaucoma. Secondary open‑angle glaucoma: assists in controlling pressure when other causes are present.

Latanoprost/Timolol may cause ocular and systemic adverse reactions.

Common Side Effects: - Eye irritation or burning sensation - Blurred vision after instillation - Redness of the conjunctiva - Itching or mild allergic reaction - Dry eye or foreign‑body sensation - Transient changes in eyelash growth

Serious or Rare Side Effects: - Severe allergic reaction (angio‑edema, anaphylaxis) - Worsening of glaucoma or sudden loss of vision - Persistent eye pain with visual disturbance - Systemic β‑blocker effects such as bradycardia, hypotension - Bronchospasm in patients with asthma or COPD - Corneal ulceration or infection

Before prescribing Latanoprost/Timolol, consider the following safety measures.

Assess cardiovascular status: evaluate for bradycardia, heart block, asthma or COPD. Monitor intraocular pressure: schedule regular ophthalmic examinations. Avoid in sulfonamide allergy: consider alternative therapy if hypersensitivity is known. Do not combine with other prostaglandin analogs: risk of additive ocular effects. Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost/Timolol can interact with other medications; awareness of major and moderate interactions is important.

Major Interactions (Avoid): - Non‑selective systemic beta‑blockers (e.g., propranolol): may cause excessive systemic β‑blockade. - Other intraocular pressure‑lowering agents (e.g., apraclonidine): risk of over‑reduction of pressure. - Sympathomimetic eye drops (e.g., phenylephrine): may antagonize the drug's effect.

Moderate Interactions (Monitor Closely): - Systemic carbonic anhydrase inhibitors: may enhance intraocular pressure reduction. - Anticholinergic drugs: may affect pupil size and ocular dynamics.